ABIVAX

Perfil de la empresa

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Descripción disponible en inglés.

Datos societarios

Sector

Salud

Industria

Biotechnology

País

Francia

Sede

7-11 Boulevard Haussmann, 75009, Paris

Empleados

98

Cotización

ABVX · Euronext Paris

Divisa

EUR

ISIN

FR0012333284

Sitio web

abivax.com